New frontiers in regenerative medicine in cardiology: the potential of Wharton's jelly mesenchymal stem cells.
Corrao S., La Rocca G., Lo Iacono M., Zummo G., Gerbino A., Farina F.
Narrative Review on Cardiovascular Disease, Immune Modulation, published in Curr Stem Cell Res Ther (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Curr Stem Cell Res Ther (2013)
- Country
- United Arab Emirates
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 23278911
- DOI
- 10.2174/1574888x11308010006
Abstract (original English)
Cardiomyopathies are still the first cause of death in the world. The identification of resident stem cells, comprising those derived from sub-endocardial stroma, suggests the possible self regeneration of the heart under autocrine/paracrine modulation in the cardiac microenvironment. Nevertheless, because of the limited in vivo regeneration potential of damaged cardiac tissue, the use of drugs and ultimately cardiac transplantation remain the common treatments of heart diseases and defects. The differentiative potential of embryonic and mesenchymal stem cells (MSCs) derived from different tissues (such as bone marrow and adipose tissue) was extensively explored in cell therapy for regenerative medicine. Many groups have been focused, in recent years, on isolation, characterization, and differentiation potential of MSCs derived from perinatal (or extraembryonic) tissues, mainly the placenta and the human umbilical cord. In this review, we summarized recent works about the stemness of Wharton's jelly stromal cells and their potential in cardiac regeneration with favourable use in cell therapy and regenerative medicine. The peculiar features of these cells, as the expression of cardiac-specific transcription factors and immunomodulatory molecules suggest that human umbilical cord may be considered as a reliable alternative source of MSC useful for advanced therapy in cardiac rege
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev